Lots of physical activity, social engagement and mentally stimulating pursuit along with a nutritious diet have long been associated with helping people stay healthy as they age. These factors might also help reduce the risks of cognitive decline and Alzheimer’s disease. clinical trials are presently testing some of these possibilities we speak.
Companies, until recently , have mostly gone in search of the same target – Amyloid-ss proteins that form aggregates or plaques in the brain of Alzheimer’s disease patients. Evidence now suggests that amyloid is deposited early during the span of the disease, even before clinical symptoms appear. So targeting amyloid in patients with mild to moderate Alzheimer’s Disease, like past failed clinical trials have done , may not be enough to stop the disease from progressing,
For people who already have some of these plaques forming, there’s not a lot that can be done until we get some disease-modifying therapy. Within the last few years, there have been quite a few [drugs] getting into Phase III clinical trials. that means larger trials with larger groups of people. They’re not prevention trials, [but they’re] just seeing whether the treatments can modify this aggregation of plaques one way or the other. There is some hope that we’ll have disease-modifying therapies in the not too distant future. There was a news item about a medicine out of canada that is showing great promise. But I can’t put an exact time of release on it.
HOPE, ALWAYS HOPE!
There is a growing focus on TAU Targets, but many of these are in an early stage. There are some though that are reaching clinical trials, such as TAURX, Therapeutics LMTX, which is now reaching Phase 111 trials for mild Alzheimer’s and frontotemporal Dementia. But advances in biomarkers and tau imaging will no doubt be needed to ensure treatments are tested on the right patients and at the right time.
Many of the large pharmaceutical companies have invested great amounts in developing treatments to target amyloid plaques. but sofar all of them have failed in the clinical trials. It is evident that some drugs are able to clear the plaques, they do not appear the degeneration of cognitive abilities. The TAU protein tangles, however , dose appear to correlate better with brain function and much modern research is aimed at removal of these.
Vaccines or immunotherapy for Alzheimer’s, unlike the regular type vaccines, would be used to treat those patients already diagnosed with Alzheimer’s rather than for disease prevention. Ongoing trials are based on the presumptive belief that, by teaching the immune system to find and attack beta-amyloid, the immune system might turn back the deposition of amyloid and thus halt the disease. Initial results using this approach in animals were acceptable, and clinical trials of the test drug AN-1792 showed results in 20% of patients. However, in 2002 it was reported that 6% of the multi-dosed participants (18 of 300) got symptoms resembling meningoencephalitis, and the trials were immediately stopped. Participants in the stopped trials continued to be followed, and 20% “developed extremely high levels of antibodies to beta-amyloid” and some showed slower progression of the disease, maintaining there memory-test levels while placebo-patients got worse.
Researchers are at the present time are evaluating many of these presumed interventions in clinical trials for their potential ability to slow the progression of Alzheimer’s disease. Researchers at these clinical trials Centers are working to recognise there research advances into new and improved treatments and preventions for AD patients while, at the same time, they are also focusing on the program’s long-term goal of finding a way to cure and possibly prevent AD.
I Have Alzheimer’s